Nektar Therapeutics (NKTR) - Net Assets
Based on the latest financial reports, Nektar Therapeutics (NKTR) has net assets worth $576.22 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($763.27 Million) and total liabilities ($187.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NKTR tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $576.22 Million |
| % of Total Assets | 75.49% |
| Annual Growth Rate | 5.85% |
| 5-Year Change | -86.78% |
| 10-Year Change | 1.94% |
| Growth Volatility | 407.82 |
Nektar Therapeutics - Net Assets Trend (1994–2025)
This chart illustrates how Nektar Therapeutics's net assets have evolved over time, based on quarterly financial data. See Nektar Therapeutics defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Nektar Therapeutics (1994–2025)
The table below shows the annual net assets of Nektar Therapeutics from 1994 to 2025. For live valuation and market cap data, see market cap of Nektar Therapeutics.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $89.83 Million | +47.90% |
| 2024-12-31 | $60.74 Million | -53.63% |
| 2023-12-31 | $130.99 Million | -64.27% |
| 2022-12-31 | $366.64 Million | -46.04% |
| 2021-12-31 | $679.51 Million | -36.92% |
| 2020-12-31 | $1.08 Billion | -23.35% |
| 2019-12-31 | $1.41 Billion | -18.18% |
| 2018-12-31 | $1.72 Billion | +1855.61% |
| 2017-12-31 | $87.83 Million | -0.34% |
| 2016-12-31 | $88.12 Million | +1270.74% |
| 2015-12-31 | $6.43 Million | -82.30% |
| 2014-12-31 | $36.33 Million | +140.41% |
| 2013-12-31 | $-89.90 Million | -291.21% |
| 2012-12-31 | $47.02 Million | -76.23% |
| 2011-12-31 | $197.81 Million | +118.19% |
| 2010-12-31 | $90.66 Million | -11.43% |
| 2009-12-31 | $102.37 Million | -46.17% |
| 2008-12-31 | $190.15 Million | -11.32% |
| 2007-12-31 | $214.44 Million | -5.56% |
| 2006-12-31 | $227.06 Million | -30.52% |
| 2005-12-31 | $326.81 Million | -30.07% |
| 2004-12-31 | $467.34 Million | +184.63% |
| 2003-12-31 | $164.19 Million | -20.59% |
| 2002-12-31 | $206.77 Million | -23.51% |
| 2001-12-31 | $270.31 Million | -2.72% |
| 2000-12-31 | $277.88 Million | +220.77% |
| 1999-12-31 | $86.63 Million | -25.24% |
| 1998-12-31 | $115.88 Million | +19.35% |
| 1997-12-31 | $97.09 Million | +176.62% |
| 1996-12-31 | $35.10 Million | +73.76% |
| 1995-12-31 | $20.20 Million | +31.17% |
| 1994-12-31 | $15.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nektar Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 375018600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $17.00K | 0.02% |
| Other Components | $3.85 Billion | 4285.89% |
| Total Equity | $89.83 Million | 100.00% |
Nektar Therapeutics Competitors by Market Cap
The table below lists competitors of Nektar Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northwest Natural Gas Co
NYSE:NWN
|
$2.06 Billion |
|
Navios Maritime Partners LP Unit
NYSE:NMM
|
$2.06 Billion |
|
Zhejiang Semir Garment Co Ltd
SHE:002563
|
$2.06 Billion |
|
Central China Securities Co Ltd
SHG:601375
|
$2.06 Billion |
|
Atul Limited
NSE:ATUL
|
$2.06 Billion |
|
Sichuan Swellfun Co Ltd
SHG:600779
|
$2.06 Billion |
|
OCADO GROUP SP.ADR 1/2
F:0OC1
|
$2.05 Billion |
|
Weifu High-Technology Group Co Ltd
SHE:000581
|
$2.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nektar Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 60,737,000 to 89,832,000, a change of 29,095,000 (47.9%).
- Net loss of 164,076,000 reduced equity.
- New share issuances of 180,850,000 increased equity.
- Other comprehensive income decreased equity by 44,000.
- Other factors increased equity by 12,365,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-164.08 Million | -182.65% |
| Share Issuances | $180.85 Million | +201.32% |
| Other Comprehensive Income | $-44.00K | -0.05% |
| Other Changes | $12.37 Million | +13.76% |
| Total Change | $- | 47.90% |
Book Value vs Market Value Analysis
This analysis compares Nektar Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.25x to 11.44x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $18.74 | $60.92 | x |
| 1995-12-31 | $15.35 | $60.92 | x |
| 1996-12-31 | $23.17 | $60.92 | x |
| 1997-12-31 | $52.80 | $60.92 | x |
| 1998-12-31 | $55.29 | $60.92 | x |
| 1999-12-31 | $38.20 | $60.92 | x |
| 2000-12-31 | $99.25 | $60.92 | x |
| 2001-12-31 | $76.31 | $60.92 | x |
| 2002-12-31 | $56.10 | $60.92 | x |
| 2003-12-31 | $44.12 | $60.92 | x |
| 2004-12-31 | $89.35 | $60.92 | x |
| 2005-12-31 | $57.06 | $60.92 | x |
| 2006-12-31 | $37.93 | $60.92 | x |
| 2007-12-31 | $35.01 | $60.92 | x |
| 2008-12-31 | $30.87 | $60.92 | x |
| 2009-12-31 | $16.55 | $60.92 | x |
| 2010-12-31 | $14.46 | $60.92 | x |
| 2011-12-31 | $26.27 | $60.92 | x |
| 2012-12-31 | $0.41 | $60.92 | x |
| 2013-12-31 | $-0.78 | $60.92 | x |
| 2014-12-31 | $4.30 | $60.92 | x |
| 2015-12-31 | $0.73 | $60.92 | x |
| 2016-12-31 | $9.47 | $60.92 | x |
| 2017-12-31 | $0.56 | $60.92 | x |
| 2018-12-31 | $9.54 | $60.92 | x |
| 2019-12-31 | $120.47 | $60.92 | x |
| 2020-12-31 | $90.49 | $60.92 | x |
| 2021-12-31 | $55.61 | $60.92 | x |
| 2022-12-31 | $29.39 | $60.92 | x |
| 2023-12-31 | $10.34 | $60.92 | x |
| 2024-12-31 | $4.43 | $60.92 | x |
| 2025-12-31 | $5.32 | $60.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nektar Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -182.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -297.07%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 3.12x
- Recent ROE (-182.65%) is below the historical average (-113.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -34.42% | -311.76% | 0.10x | 1.12x | $-6.84 Million |
| 1995 | -38.12% | -226.47% | 0.15x | 1.15x | $-9.72 Million |
| 1996 | -28.49% | -144.93% | 0.17x | 1.18x | $-13.51 Million |
| 1997 | -10.28% | -61.44% | 0.14x | 1.23x | $-19.69 Million |
| 1998 | -15.84% | -84.22% | 0.16x | 1.16x | $-29.94 Million |
| 1999 | -44.38% | -92.96% | 0.18x | 2.62x | $-47.11 Million |
| 2000 | -35.05% | -188.66% | 0.08x | 2.27x | $-125.19 Million |
| 2001 | -92.49% | -322.72% | 0.12x | 2.47x | $-277.04 Million |
| 2002 | -51.97% | -113.31% | 0.16x | 2.93x | $-128.15 Million |
| 2003 | -28.43% | -43.93% | 0.17x | 3.76x | $-63.10 Million |
| 2004 | -21.80% | -89.16% | 0.15x | 1.59x | $-148.62 Million |
| 2005 | -56.64% | -146.59% | 0.15x | 2.63x | $-217.79 Million |
| 2006 | -68.16% | -71.08% | 0.28x | 3.38x | $-177.47 Million |
| 2007 | -15.28% | -12.00% | 0.38x | 3.38x | $-54.20 Million |
| 2008 | -18.06% | -38.07% | 0.16x | 2.95x | $-53.35 Million |
| 2009 | -100.15% | -142.52% | 0.12x | 5.62x | $-112.76 Million |
| 2010 | -41.85% | -23.85% | 0.31x | 5.75x | $-47.00 Million |
| 2011 | -67.73% | -187.43% | 0.12x | 3.07x | $-153.76 Million |
| 2012 | -365.51% | -211.67% | 0.16x | 10.59x | $-176.56 Million |
| 2013 | 0.00% | -108.79% | 0.34x | 0.00x | $-153.02 Million |
| 2014 | -148.40% | -26.86% | 0.45x | 12.16x | $-57.55 Million |
| 2015 | -1262.67% | -35.17% | 0.46x | 78.09x | $-81.82 Million |
| 2016 | -174.21% | -92.80% | 0.29x | 6.46x | $-162.34 Million |
| 2017 | -110.09% | -31.42% | 0.60x | 5.79x | $-105.47 Million |
| 2018 | 39.67% | 57.09% | 0.55x | 1.25x | $509.56 Million |
| 2019 | -31.36% | -384.47% | 0.06x | 1.41x | $-581.21 Million |
| 2020 | -41.26% | -290.65% | 0.10x | 1.43x | $-552.17 Million |
| 2021 | -77.09% | -514.03% | 0.09x | 1.64x | $-591.79 Million |
| 2022 | -100.43% | -399.98% | 0.13x | 1.94x | $-404.86 Million |
| 2023 | -210.75% | -306.31% | 0.23x | 3.04x | $-289.15 Million |
| 2024 | -195.86% | -120.86% | 0.32x | 5.00x | $-125.03 Million |
| 2025 | -182.65% | -297.07% | 0.20x | 3.12x | $-173.06 Million |
Industry Comparison
This section compares Nektar Therapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | $576.22 Million | -34.42% | 0.32x | $2.06 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more